SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment

SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment

Vito Racanelli, Marcella Prete, Elvira Favoino, Giacomo Catacchio, Federico Perosa

The current pandemic coronavirus, SARS-CoV-2, is a global health emergency because of its highly contagious nature, the great number of patients requiring intensive care therapy, and the high fatality rate. In the absence of specific antiviral drugs, passive prophylaxis, or a vaccine, the treatment aim in these patients is to prevent the potent virus-induced inflammatory stimuli from leading to the acute respiratory distress syndrome (ARDS), which has a severe prognosis. Here, the mechanism of action and the rationale for employing immunological strategies, which range from traditional chemically synthesized drugs, anti-cytokine antibodies, human immunoglobulin for intravenous use, to vaccines, are reviewed.

2020

inflammation, anti-cytokine antibodies, acute respiratory syndrome, SARS-CoV-2, COVID-19, human immunoglobulin for intravenous use

DOI: 10.3390/ijms21093377

International Journal of Molecular Sciences

MDPI AG

Biology (General), Chemistry